Cellens Is Collaborating With Bruker BioAFM, A Business Unit Of Bruker, To Develop The World's First Clinical Diagnostic Tests That Leverage Multi-parametric, Single-cell Biophysical Markers And Machine Learning
Portfolio Pulse from Benzinga Newsdesk
Cellens is collaborating with Bruker BioAFM, a unit of Bruker, to develop clinical diagnostic tests using multi-parametric, single-cell biophysical markers and machine learning. The technology has shown high sensitivity and specificity in detecting bladder cancer from urine samples in pilot studies.
June 25, 2024 | 11:06 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bruker BioAFM's collaboration with Cellens to develop advanced diagnostic tests for bladder cancer could enhance Bruker's market position in the medical diagnostics field. The technology's high sensitivity and specificity in pilot studies are promising.
The collaboration with Cellens positions Bruker BioAFM at the forefront of innovative diagnostic technologies. The promising results from pilot studies suggest potential market success, likely driving positive sentiment and short-term stock price appreciation for BRKR.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80